DE60225274D1 - Chinolinderivate als liganden für den neuropeptid-y-rezeptor - Google Patents

Chinolinderivate als liganden für den neuropeptid-y-rezeptor

Info

Publication number
DE60225274D1
DE60225274D1 DE60225274T DE60225274T DE60225274D1 DE 60225274 D1 DE60225274 D1 DE 60225274D1 DE 60225274 T DE60225274 T DE 60225274T DE 60225274 T DE60225274 T DE 60225274T DE 60225274 D1 DE60225274 D1 DE 60225274D1
Authority
DE
Germany
Prior art keywords
neuropeptide
ligands
receptor
chinoline derivatives
chinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60225274T
Other languages
English (en)
Other versions
DE60225274T2 (de
Inventor
Werner Mueller
Werner Neidhart
Philippe Pflieger
Jean-Marc Plancher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60225274D1 publication Critical patent/DE60225274D1/de
Application granted granted Critical
Publication of DE60225274T2 publication Critical patent/DE60225274T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60225274T 2001-05-21 2002-05-08 Chinolinderivate als liganden für den neuropeptid-y-rezeptor Expired - Fee Related DE60225274T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112370 2001-05-21
EP01112370 2001-05-21
PCT/EP2002/005120 WO2002094789A1 (en) 2001-05-21 2002-05-08 Quinoline derivatives as ligands for the neuropeptide y receptor

Publications (2)

Publication Number Publication Date
DE60225274D1 true DE60225274D1 (de) 2008-04-10
DE60225274T2 DE60225274T2 (de) 2009-03-26

Family

ID=8177497

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60225274T Expired - Fee Related DE60225274T2 (de) 2001-05-21 2002-05-08 Chinolinderivate als liganden für den neuropeptid-y-rezeptor

Country Status (19)

Country Link
US (2) US6818767B2 (de)
EP (1) EP1395564B1 (de)
JP (1) JP3715280B2 (de)
KR (1) KR100621287B1 (de)
CN (1) CN100376557C (de)
AR (1) AR035979A1 (de)
AT (1) ATE387428T1 (de)
AU (1) AU2002338896B2 (de)
BR (1) BR0209957A (de)
CA (1) CA2446324A1 (de)
DE (1) DE60225274T2 (de)
ES (1) ES2300478T3 (de)
GT (1) GT200200090A (de)
MX (1) MXPA03010565A (de)
PA (1) PA8545301A1 (de)
PE (1) PE20021155A1 (de)
UY (1) UY27300A1 (de)
WO (1) WO2002094789A1 (de)
ZA (1) ZA200308783B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US7084156B2 (en) * 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1474145B1 (de) * 2002-02-04 2008-04-23 F. Hoffmann-La Roche Ag Chinolinderivate als npy antagonisten
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
KR100647932B1 (ko) 2002-07-05 2006-11-23 에프. 호프만-라 로슈 아게 퀴나졸린 유도체
WO2004014884A1 (en) 2002-08-07 2004-02-19 F. Hoffmann-La Roche Ag Thiazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
JP4765627B2 (ja) 2003-09-22 2011-09-07 Msd株式会社 新規ピペリジン誘導体
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
AU2006253312B2 (en) 2005-05-30 2011-08-18 Msd K.K. Novel piperidine derivative
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
EP2145884B1 (de) 2007-04-02 2014-08-06 Msd K.K. Indoledionderivat
WO2008141077A1 (en) * 2007-05-10 2008-11-20 Janssen Pharmaceutica N.V. Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
WO2008142384A1 (en) 2007-05-17 2008-11-27 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
TW200907022A (en) * 2007-06-01 2009-02-16 Du Pont Chrysenes for green luminescent applications
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
SI2220076T1 (sl) * 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Msd株式会社 アルキルアミノピリジン誘導体
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Msd株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AU2018301681B2 (en) * 2017-07-14 2022-07-14 Innate Tumor Immunity, Inc. NLRP3 modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU43730A1 (de) * 1962-06-14 1963-07-13
US3272824A (en) * 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US3812127A (en) * 1966-10-31 1974-05-21 Pfizer 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035917C (en) 1990-02-13 2001-10-02 John L. Krstenansky Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AU719392B2 (en) * 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
WO2000009123A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
AU1047401A (en) * 1999-11-08 2001-06-06 Cytion Sa Apparatus and methods for positioning and analyzing biological membranous objects
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists

Also Published As

Publication number Publication date
CN100376557C (zh) 2008-03-26
AR035979A1 (es) 2004-07-28
US6818767B2 (en) 2004-11-16
ES2300478T3 (es) 2008-06-16
EP1395564B1 (de) 2008-02-27
US20020198194A1 (en) 2002-12-26
KR20030096416A (ko) 2003-12-24
WO2002094789A1 (en) 2002-11-28
UY27300A1 (es) 2002-11-29
KR100621287B1 (ko) 2006-09-13
JP3715280B2 (ja) 2005-11-09
PA8545301A1 (es) 2003-01-24
ATE387428T1 (de) 2008-03-15
GT200200090A (es) 2003-06-19
CN1522249A (zh) 2004-08-18
BR0209957A (pt) 2004-03-30
CA2446324A1 (en) 2002-11-28
JP2004536066A (ja) 2004-12-02
ZA200308783B (en) 2005-02-11
MXPA03010565A (es) 2004-03-02
AU2002338896B2 (en) 2006-04-27
US20050049413A1 (en) 2005-03-03
PE20021155A1 (es) 2002-12-17
EP1395564A1 (de) 2004-03-10
DE60225274T2 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
DE60225274D1 (de) Chinolinderivate als liganden für den neuropeptid-y-rezeptor
DE60218340D1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
DE60331751D1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
DE60336811D1 (de) Neue benzimidazolderivate
ATE316957T1 (de) Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
DE60331444D1 (de) 1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden
ATE304008T1 (de) Benzimidiazole und pyridylimidazole derivate als liganden für gaba rezeptoren
ATE396191T1 (de) Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden
DE60129746D1 (de) Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
DE60207815D1 (de) 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
ATE392897T1 (de) Chinolinderivate als npy antagonisten
DE60110844D1 (de) Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
ATE335477T1 (de) Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden
DE602004019208D1 (de) Neue benzimidazolderivate
ATE327232T1 (de) Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden
DE60206652D1 (de) Benzothiazolderivate als adenosin-rezeptor-liganden
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
DE602004028821D1 (de) Pyrrolidiniumderivative als liganden für den muscarinen m3-rezeptor
DE60316180D1 (de) Aminoalkoxyindol-derivate als 5-ht6-rezeptorliganden zur bekämpfung von zns-krankheiten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE287405T1 (de) 5-halogen-6-phenyl-7-fluoroalkylamino- triazolopyrimidine als fungizide
ATE374183T1 (de) Nk1-antagonisten
ATE293619T1 (de) Pyridinderivate als nmda-rezeptorliganden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee